Skip to main content

Advertisement

Springer Nature Link
Log in

Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) belongs to the vasoactive intestinal peptide-secretin-glucagon peptide family, isolated first from ovine hypothalamus. The diverse physiological effects of PACAP are known mainly from animal experiments, including several actions in endocrine glands. Alteration of PACAP expression has been shown in several tumors, but changes in expression of PACAP and its specific PAC1 receptor in human thyroid gland pathologies have not yet been investigated. Therefore, the aim of the present study was to investigate expression of PACAP and its PAC1 receptor in human thyroid papillary carcinoma, the most common endocrine malignant tumor. PACAP and PAC1 receptor expressions were investigated from thyroid gland samples of patients with papillary carcinomas. The staining intensity of follicular epithelial cells and thyroid colloid of tumor tissue was compared to that of tumor-free tissue in the same thyroid glands in a semi-quantitative way. Our results reveal that both PACAP(-like) and PAC1 receptor(-like) immunoreactivities are altered in papillary carcinoma. Stronger PACAP immunoreactivity was observed in active follicles. Colloidal PACAP immunostaining was either lacking or very weak, and more tumorous cells displayed strong apical immunoreactivity. Regarding PAC1 receptor, cells of the normal thyroid tissue showed strong granular expression, which was lacking in the tumor cells. The cytoplasm of tumor cells displayed weak, minimal staining, while in a few tumor cells we observed strong PAC1 receptor expression. This pattern was similar to that observed in the PACAP expression, but fewer in number. In summary, we showed alteration of PACAP and PAC1 receptor expression in human thyroid papillary carcinoma, indicating that PACAP regulation is disturbed in tumorous tissue of the thyroid gland. The exact role of PACAP in thyroid tumor growth should be further explored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

References

  • Baranowska-Bik A, Bik W, Wolinska-Witort E, Chmielowska M, Martynska L, Baranowska B (2006) Can PACAP-38 modulate immune and endocrine responses during lipopolysaccharide (LPS)-induced acute inflammation? Ann N Y Acad Sci 1070:156–160

    Article  CAS  PubMed  Google Scholar 

  • Bik W, Wolinska-Witort E, Baranowska-Bik A, Martynska L, Chmielowska M, Baranowska B (2007) PACAP 38 inhibits adiponectin release. Neuro Endocrinol Lett 28:166–169

    CAS  PubMed  Google Scholar 

  • Bukovics P, Czeiter E, Amrein K, Kovacs N, Pal J, Tamas A, Bagoly T, Helyes Z, Buki A, Reglodi D (2014) Changes of PACAP level in cerebrospinal fluid and plasma of patients with severe traumatic brain injury. Peptides 60:18–22

    Article  CAS  PubMed  Google Scholar 

  • Casperini L, Piubelli C, Carboni L (2012) Proteomics of rat hypothalamus, hippocampus and pre-frontal/frontal cortex after central administration of the neuropeptide PACAP. Mol Biol Rep 39:2921–2935

    Article  Google Scholar 

  • Chen W, Inui T, Hachiya T, Ochi Y, Nakajima Y, Kajita Y (1993) Stimulatory action of pituitary adenylate cyclase-activating polypeptide (PACAP) on thyroid gland. Biochem Biophys Res Commun 94:923–929

    Article  Google Scholar 

  • Chiodera P, Volpi R, Capretti L, Caffarri G, Magotti MG, Coiro V (1996) Effects of intravenously infused pituitary adenylate cyclase-activating polypeptide on adenohypophyseal hormone secretion in normal men. Neuroendocrinology 64:242–246

    Article  CAS  PubMed  Google Scholar 

  • Clason TA, Girard BM, May V, Parsons RL (2016) Activation of MEK/ERK signaling by PACAP in guinea pig cardiac neurons. J Mol Neurosci 59:309–316

    Article  CAS  PubMed  Google Scholar 

  • Cochaud S, Chevrier L, Meunier AC, Brillet T, Chadéneau C, Muller JM (2010) The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration. Neuropeptides 44:373–383

    Article  CAS  PubMed  Google Scholar 

  • Culler MD, Paschall CS (1991) Pituitary adenylate cyclase-activating polypeptide (PACAP) potentiates the gonadotropin-releasing activity of luteinizing hormone-releasing hormone. Endocrinology 129:2260–2262

    Article  CAS  PubMed  Google Scholar 

  • Dufes C, Alleaume C, Montoni A, Olivier JC, Muller JM (2003) Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro. J Mol Neurosci 21:91–102

    Article  CAS  PubMed  Google Scholar 

  • Duh QY, Gum ET, Gerend PL, Raper SE, Clark OH (1985) Epidermal growth factor receptors in normal and neoplastic thyroid tissue. Surgery 98:1000–1007

    CAS  PubMed  Google Scholar 

  • Duh QY, Siperstein AE, Miller RA, Sancho JJ, Demeure MJ, Clark OH (1990) Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues. World J Surg 14:410–417

    Article  CAS  PubMed  Google Scholar 

  • Egri P, Fekete C, Dénes Á, Reglődi D, Hashimoto H, Fülöp BD, Gereben B (2016) Pituitary adenylate cyclase-activating polypeptide (PACAP) regulates the hypothalamo-pituitary-thyroid (HPT) axis via type 2 deiodinase in male mice. Endocrinology 157:2356–2366

    Article  CAS  PubMed  Google Scholar 

  • Fahrenkrug J, Hannibal J (2011) Localisation of the neuropeptide PACAP and its receptors in the rat parathyroid and thyroid glands. Gen Comp Endocrinol 171:105–113

    Article  CAS  PubMed  Google Scholar 

  • Faluhelyi N, Reglodi D, Csernus V (2006) The effects of PACAP and VIP on the in vitro melatonin secretion from the embryonic chicken pineal gland. Ann N Y Acad Sci 1070:271–275

    Article  CAS  PubMed  Google Scholar 

  • Ges IA, Brindley RL, Currie KP, Baudenbacher FJ (2013) A microfluidic platform for chemical stimulation and real time analysis of catecholamine secretion from neuroendocrine cells. Lab Chip 13:4663–4673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Girard BM, Malley SE, Mathews MM, May V, Vizzard MA (2016) Intravesical PAC1 receptor antagonist, PACAP(6-38), reduces urinary bladder frequency and pelvic sensitivity in NGF-OE mice. J Mol Neurosci 59:290–299

    Article  CAS  PubMed  Google Scholar 

  • Gracia-Navarro F, Lamacz M, Tonon MC, Vaudry H (1992) Pituitary adenylate cyclase-activating polypeptide stimulates calcium mobilization in amphibian pituitary cells. Endocrinology 131:1069–1074

    CAS  PubMed  Google Scholar 

  • Guo S, Vollesen AL. Hansen YB, Frandsen E, Andersen MR, Amin FM, Fahrenkrug J, Olesen J, Ashina M (2016) Part II: biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia. in press

  • Gutierrez-Canas I, Rodriguez-Henche N, Bolanos O, Carmena MJ, Prieto JC, Juarranz MG (2003) VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. Br J Pharmacol 139:1050–1058

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Halvorson LM (2014) PACAP modulates GnRH signaling in gonadotropes. Mol Cell Endocrinol 385:45–55

    Article  CAS  PubMed  Google Scholar 

  • Han P, Caselli RJ, Baxter L, Serrano G, Yin J, Beach TG, Reiman EM, Shi J (2015) Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease. JAMA Neurol 72:333–339

    Article  PubMed  Google Scholar 

  • Harmar AJ, Sheward WJ, Morrison CF, Waser B, Gugger M, Reubi JC (2004) Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Endocrinology 145:1203–1210

    Article  CAS  PubMed  Google Scholar 

  • Hart GR, Gowing H, Burrin JM (1992) Effects of a novel hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide, on pituitary hormone release in rats. J Endocrinol 134:33–41

    Article  CAS  PubMed  Google Scholar 

  • Hayez N, Harfi I, Lema-Kisoka R, Svoboda M, Corazza F, Sariban E (2004) The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells. J Neuroimmunol 149:167–181

    Article  CAS  PubMed  Google Scholar 

  • Hölting T, Duh OY, Clark OH, Herfarth C (1995) Growth and invasion of differentiated thyroid gland carcinoma: importance of signal transduction. Langenbecks Arch Chir 380:96–101

    Article  PubMed  Google Scholar 

  • Jung MJ, Kwon SK (2014) Expression of glucagon-like peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance. Endocrinol Metab (Seoul) 29:536–544

    Article  Google Scholar 

  • Jung S, Yi L, Jeong D, Kim J, An S, Oh TJ, Kim CH, Kim CJ, Yang Y, Kim KI, Lim JS, Lee MS (2011) The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer. Oncol Rep 25:245–252

    CAS  PubMed  Google Scholar 

  • Kanasaki H, Oride A, Mijiddorj T, Kyo S (2015a) Role of thyrotropin-releasing hormone in prolactin-producing cell models. Neuropeptides 54:73–77

    Article  CAS  PubMed  Google Scholar 

  • Kanasaki H, Oride A, Kyo S (2015b) Role of pituitary adenylate cyclase-activating polypeptide in modulating hypothalamus-pituitary neuroendocrine functions in mouse cell models. J Neuroendocrinol 27:1–7

    Article  CAS  PubMed  Google Scholar 

  • Kanno Y, Ishisaki A, Yoshida M, Nakajima K, Tokuda H, Numata O, Kozawa O (2005) Adenylyl cyclase-cAMP system inhibits thyroid hormone-stimulated osteocalcin synthesis in osteoblasts. Mol Cell Endocrinol 229:75–82

    Article  CAS  PubMed  Google Scholar 

  • Koves K (2016) Presence and role of PACAP in endocrine glands of mammals. In: Reglodi D, Tamas A (eds) Pituitary adenylate cyclase activating polypeptide–PACAP. Springer Nature, New York in press

    Google Scholar 

  • Lloyd RV, Buehler D, Khanafshar E (2011) Papillary thyroid carcinoma variants. Head Neck Pathol 5:51–56

    Article  PubMed  PubMed Central  Google Scholar 

  • Mäkinen T, Pekonen F, Franssila K, Lamberg BA (1988) Receptors for epidermal growth factor and thyrotropin in thyroid carcinoma. Acta Endocrinol 117:45–50

    PubMed  Google Scholar 

  • Matsumoto H, Sakamoto A, Fujiwara M, Yano Y, Shishido-Hara Y, Fujioka Y, Kamma H (2008) Cyclic AMP-mediated growth suppression and MAPK phosphorylation in thyroid papillary carcinoma cells. Mol Med Rep 1:245–249

    CAS  PubMed  Google Scholar 

  • Matsumoto M, Nakamachi T, Watanabe J, Sugiyama K, Ohtaki H, Murai N, Sasaki S, Xu Z, Hashimoto H, Seki T, Miyazaki A, Shioda S (2016) Pituitary adenylate cyclase-activating polypeptide (PACAP) is involved in adult mouse hippocampal neurogenesis after stroke. J Mol Neurosci 59:270–279

    Article  CAS  PubMed  Google Scholar 

  • Maugeri G, Grazia D’Amico A, Reitano R, Magro G, Cavallaro S, Salomone S, D'Agata V (2016) PACAP and VIP inhibit the invasiveness of glioblastoma cells exposed to hypoxia through the regulation of HIFs and EGFR expression. Front Pharmacol 7:139

    Article  PubMed  PubMed Central  Google Scholar 

  • Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38. Biochem Biophys Res Commun 170:643–648

    Article  CAS  PubMed  Google Scholar 

  • Moody TW, Jensen RT (2016) PACAP and cancer. In: Reglodi D, Tamas A (eds) Pituitary adenylate cyclase activating polypeptide – PACAP. Springer Nature, New York, p 795–814

  • Moody TW, Chan D, Fahrenkrug J, Jensen RT (2003) Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 9:495–509

    Article  CAS  PubMed  Google Scholar 

  • Moody TW, Nuche-Berenguer B, Moreno P, Jensen RT (2015) CI-988 inhibits EGFR transactivation and proliferation caused by addition of CCK/gastrin to lung cancer cells. J Mol Neurosci 56:663–672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moody TW, Nuche-Berenguer B, Jensen RT (2016) Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. Curr Opin Endocrinol Diabetes Obes 23:38–47

    Article  CAS  PubMed  Google Scholar 

  • Nakamura K, Nakamachi T, Endo K, Ito K, Machida T, Oka T, Hori M, Ishizaka K, Shioda S (2014) Distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) in the human testis and in testicular germ cell tumors. Andrologia 46:465–471

    Article  CAS  PubMed  Google Scholar 

  • Nemetz N, Abad C, Lawson G, Nobuta H, Chhith S, Duong L, Tse G, Braun J, Waschek JA (2008) Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP. Int J Cancer 122:1803–1809

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ogren SO, Kuteeva E, Elvander-Tottie E, Hökfelt T (2010) Neuropeptides in learning and memory processes with focus on galanin. Eur J Pharmacol 626:9–17

    Article  PubMed  Google Scholar 

  • Oka H, Jin L, Kulig E, Scheithauer BW, Lloyd RV (1999) Pituitary adenylate cyclase activating polypeptide inhibits transforming growth factor-β1-induced apoptosis in a human pituitary adenoma cell line. Am J Pathol 155:1893–1900

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Okada R, Yamamoto K, Ito Y, Mochida H, Tonon MC, Fournier A, Leprince J, Vaudry H, Kikuyama S (2007) VIP and PACAP stimulate TSH release from the bullfrog pituitary. Peptides 28:1784–1789

    Article  CAS  PubMed  Google Scholar 

  • Padua D, JP V, Germano PM, Pisegna JR (2016) The role of neuropeptides in mouse models of colitis. J Mol Neurosci 59:203–210

    Article  CAS  PubMed  Google Scholar 

  • Park HJ, Choi BC, Song SJ, Lee DS, Roh J, Chun SY (2010) Luteinizing hormone-stimulated pituitary adenylate cyclase-activating polypeptide system and its role in progesterone production in human luteinized granulosa cells. Endocr J 57:127–134

    Article  CAS  PubMed  Google Scholar 

  • Rawlings SR, Hezareh M (1996) Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr Rev 17:4–29

    CAS  PubMed  Google Scholar 

  • Reglodi D, Tamas A, Koppan M, Szogyi D, Welke L (2012) Role of PACAP in female fertility and reproduction at gonadal level – recent advances. Front Endocrinol (Lausanne) 3:155

    Google Scholar 

  • Reglodi D, Helyes ZS, Németh J, Vass R, Tamas A (2016) PACAP as a potential biomarker – alterations of PACAP levels in human physiological and pathological conditions. In: Pituitary adenylate cyclase activating polypeptide – PACAP. Springer, p 815–832

  • Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, Norrholm SD, Kilaru V, Smith AK, Myers AJ, Ramirez M, Engel A, Hammack SE, Toufexis D, Braas KM, Binder EB, May V (2011) Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470:492–497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Reubi JC (2000) vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci 921:1–25

    Article  CAS  PubMed  Google Scholar 

  • Sandor B, Fintor K, Reglodi D, Fulop DB, Helyes Z, Szanto I, Nagy P, Hashimoto H, Tamas A (2016) Structural and morphometric comparison of lower incisors in PACAP-deficient and wild-type mice. J Mol Neurosci 59:300–308

    Article  CAS  PubMed  Google Scholar 

  • Sanlioglu AD, Karacay B, Balci MK, Griffith TS, Sanlioglu S (2012) Therapeutic potential of VIP vs PACAP in diabetes. J Mol Endocrinol 49:R157–R167

    Article  CAS  PubMed  Google Scholar 

  • Schulz S, Röcken C, Mawrin C, Weise W, Höllt V, Schulz S (2004) Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Clin Cancer Res 10:8235–8242

    Article  CAS  PubMed  Google Scholar 

  • Schulz S, Mann A, Novakhov B, Piggins HD, Lupp A (2015) VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235. Endocr Connect 4:18–26

    Article  PubMed  PubMed Central  Google Scholar 

  • Shang X, Zhong X, Tian X (2016) Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy. Tumour Biol in press

  • Sharma A, Walters J, Gozes Y, Fridkin M, Brenneman D, Gozes I, Moody TW (2001) A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells. J Mol Neurosci 17:331–339

    Article  CAS  PubMed  Google Scholar 

  • Siperstein AE, Miller RA, Clark OH (1988) Stimulatory effect of vasoactive intestinal polypeptide on human normal and neoplastic thyroid tissue. Surgery 104:985–991

    CAS  PubMed  Google Scholar 

  • Szanto Z, Sarszegi Z, Reglodi D, Nemeth J, Szabadfi K, Kiss P, Varga A, Banki E, Csanaky K, Gaszner B, Pinter O, Szalai Z, Tamas A (2012) PACAP immunoreactivity in human malignant tumor samples and cardiac diseases. J Mol Neurosci 48:667–673

    Article  CAS  PubMed  Google Scholar 

  • Tajti J, Tuka B, Botz B, Helyes Z, Vecsei L (2015) Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine. CNS Neurol Disord Drug Targets 14:540–553

    Article  CAS  PubMed  Google Scholar 

  • Tamas A, Javorhazy A, Reglodi D, Sarlos DP, Banyai D, Semjen D, Nemeth J, Lelesz B, Fulop DB, Szanto Z (2016) Examination of PACAP-like immunoreactivity in urogenital tumor samples. J Mol Neurosci 59:177–183

    Article  CAS  PubMed  Google Scholar 

  • Tezelman S, Siperstein AE, Duh QY, Wong MG, Clark OH (1996) Desensitization of cyclic adenosine 3,5′-monophosphate response to thyrotropin in normal and primary or metastatic papillary thyroid cancer cells in vitro. Surgery 120:926–933

    Article  CAS  PubMed  Google Scholar 

  • Tronko M, Mabuchi K, Bogdanova T, Hatch M, Likhtarev I, Bouville A, Oliynik V, McConnell R, Shpak V, Zablotska L, Tereshchenko V, Brenner A, Zamotayeva G (2012) Thyroid cancer in Ukraine after the Chernobyl accident (in the framework of the Ukraine-US thyroid project). J Radiol Prot 32:N65–N69

    Article  PubMed  PubMed Central  Google Scholar 

  • Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283–357

    Article  CAS  PubMed  Google Scholar 

  • Vertongen P, Camby I, Darro F, Kiss R, Robberecht P (1996) VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor. Neuropeptides 30:491–496

    Article  CAS  PubMed  Google Scholar 

  • Wojcieszak J, Zawilska JB (2014) PACAP38 and PACAP6-38 exert cytotoxic activity against human retinoblastoma Y79 cells. J Mol Neurosci 54:463–468

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yashiro T, Ohba Y, Murakami H, Obara T, Tsushima T, Fujimoto Y, Shizume K, Ito K (1989) Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. Acta Endocrinol 121:112–120

    CAS  PubMed  Google Scholar 

  • Zia F, Fagarasan M, Bitar K, Coy DH, Pisegna JR, Wank SA, Moody TW (1995) Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells. Cancer Res 55:4886–4891

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by OTKA104984, 119759, PTE ÁOK KA Research Grant. The present scientific contribution is dedicated to the 650th anniversary of the foundation of the University of Pécs, Hungary.

Author information

Authors and Affiliations

  1. Jakob Henle Institute for Pathology and Neuropathology, Heidelberg, Germany

    Sebastian Bardosi & Attila Bardosi

  2. 2nd Department of Internal Medicine, University of Pecs, Pecs, Hungary

    Zsuzsanna Nagy

  3. Department of Anatomy, University of Pecs, 7624, Szigeti u 12, Pecs, Hungary

    Dora Reglodi

Authors
  1. Sebastian Bardosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Attila Bardosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zsuzsanna Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dora Reglodi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dora Reglodi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bardosi, S., Bardosi, A., Nagy, Z. et al. Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma. J Mol Neurosci 60, 171–178 (2016). https://doi.org/10.1007/s12031-016-0823-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-016-0823-7

Keywords

Search

Navigation